Literature DB >> 32121523

Brugada Syndrome: Oligogenic or Mendelian Disease?

Michelle M Monasky1, Emanuele Micaglio1, Giuseppe Ciconte1, Carlo Pappone1.   

Abstract

Brugada syndrome (BrS) is diagnosed by a coved-type ST-segment elevation in the right precordial leads on the electrocardiogram (ECG), and it is associated with an increased risk of sudden cardiac death (SCD) compared to the general population. Although BrS is considered a genetic disease, its molecular mechanism remains elusive in about 70-85% of clinically-confirmed cases. Variants occurring in at least 26 different genes have been previously considered causative, although the causative effect of all but the SCN5A gene has been recently challenged, due to the lack of systematic, evidence-based evaluations, such as a variant's frequency among the general population, family segregation analyses, and functional studies. Also, variants within a particular gene can be associated with an array of different phenotypes, even within the same family, preventing a clear genotype-phenotype correlation. Moreover, an emerging concept is that a single mutation may not be enough to cause the BrS phenotype, due to the increasing number of common variants now thought to be clinically relevant. Thus, not only the complete list of genes causative of the BrS phenotype remains to be determined, but also the interplay between rare and common multiple variants. This is particularly true for some common polymorphisms whose roles have been recently re-evaluated by outstanding works, including considering for the first time ever a polygenic risk score derived from the heterozygous state for both common and rare variants. The more common a certain variant is, the less impact this variant might have on heart function. We are aware that further studies are warranted to validate a polygenic risk score, because there is no mutated gene that connects all, or even a majority, of BrS cases. For the same reason, it is currently impossible to create animal and cell line genetic models that represent all BrS cases, which would enable the expansion of studies of this syndrome. Thus, the best model at this point is the human patient population. Further studies should first aim to uncover genetic variants within individuals, as well as to collect family segregation data to identify potential genetic causes of BrS.

Entities:  

Keywords:  Brugada syndrome; SCN5A; arrhythmia; channelopathy; functional studies; genetic testing; mutation; segregation analysis; sodium channel; sudden cardiac death

Year:  2020        PMID: 32121523     DOI: 10.3390/ijms21051687

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  19 in total

1.  Identifying digenic disease genes via machine learning in the Undiagnosed Diseases Network.

Authors:  Souhrid Mukherjee; Joy D Cogan; John H Newman; John A Phillips; Rizwan Hamid; Jens Meiler; John A Capra
Journal:  Am J Hum Genet       Date:  2021-09-15       Impact factor: 11.025

2.  Compendium of causative genes and their encoded proteins for common monogenic disorders.

Authors:  Tucker L Apgar; Charles R Sanders
Journal:  Protein Sci       Date:  2021-09-21       Impact factor: 6.993

3.  Novel SCN5A p.Val1667Asp Missense Variant Segregation and Characterization in a Family with Severe Brugada Syndrome and Multiple Sudden Deaths.

Authors:  Michelle M Monasky; Emanuele Micaglio; Giuseppe Ciconte; Ilaria Rivolta; Valeria Borrelli; Andrea Ghiroldi; Sara D'Imperio; Anna Binda; Dario Melgari; Sara Benedetti; Predrag Mitrovic; Luigi Anastasia; Valerio Mecarocci; Žarko Ćalović; Giorgio Casari; Carlo Pappone
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

4.  Brugada syndrome genetics is associated with phenotype severity.

Authors:  Giuseppe Ciconte; Michelle M Monasky; Vincenzo Santinelli; Emanuele Micaglio; Gabriele Vicedomini; Luigi Anastasia; Gabriele Negro; Valeria Borrelli; Luigi Giannelli; Francesca Santini; Carlo de Innocentiis; Roberto Rondine; Emanuela T Locati; Andrea Bernardini; Beniamino C Mazza; Valerio Mecarocci; Žarko Ćalović; Andrea Ghiroldi; Sara D'Imperio; Sara Benedetti; Chiara Di Resta; Ilaria Rivolta; Giorgio Casari; Enrico Petretto; Carlo Pappone
Journal:  Eur Heart J       Date:  2021-03-14       Impact factor: 29.983

5.  Evaluating the Use of Genetics in Brugada Syndrome Risk Stratification.

Authors:  Michelle M Monasky; Emanuele Micaglio; Emanuela T Locati; Carlo Pappone
Journal:  Front Cardiovasc Med       Date:  2021-04-21

6.  Analysis of Brugada syndrome loci reveals that fine-mapping clustered GWAS hits enhances the annotation of disease-relevant variants.

Authors:  Mel Lina Pinsach-Abuin; Bernat Del Olmo; Adrian Pérez-Agustin; Jesus Mates; Catarina Allegue; Anna Iglesias; Qi Ma; Daria Merkurjev; Sergiy Konovalov; Jing Zhang; Farah Sheikh; Amalio Telenti; Josep Brugada; Ramon Brugada; Melissa Gymrek; Julia di Iulio; Ivan Garcia-Bassets; Sara Pagans
Journal:  Cell Rep Med       Date:  2021-04-20

7.  Ventricular Tachyarrhythmia Risk in Paediatric/Young vs. Adult Brugada Syndrome Patients: A Territory-Wide Study.

Authors:  Sharen Lee; Wing Tak Wong; Ian Chi Kei Wong; Chloe Mak; Ngai Shing Mok; Tong Liu; Gary Tse
Journal:  Front Cardiovasc Med       Date:  2021-06-11

8.  Commentary: Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the CACNA1 Gene Associated With Brugada Syndrome.

Authors:  Michelle M Monasky; Carola Rutigliani; Emanuele Micaglio; Carlo Pappone
Journal:  Front Physiol       Date:  2021-06-09       Impact factor: 4.566

Review 9.  Role of Non-Coding Variants in Brugada Syndrome.

Authors:  Adrian Pérez-Agustín; Mel Lina Pinsach-Abuin; Sara Pagans
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

Review 10.  Update on Genetic Basis of Brugada Syndrome: Monogenic, Polygenic or Oligogenic?

Authors:  Oscar Campuzano; Georgia Sarquella-Brugada; Sergi Cesar; Elena Arbelo; Josep Brugada; Ramon Brugada
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.